Replies to post #85753 on $heff's $tation of $tocks & $olid DD

[kklar1]

$CPRX $3.31 This name has lots of catalysts lined up. I'm in half a tranche (1/8th position) at $3.50, watching the price action following the offering and will add below $3.25.

I would recommend patience and incremental adds until we see which way this is going. There's no need to rush it in my mind.

My notes read: Pivotal P3 trial met primary & secondary endpoints to support planned start of rolling NDA submission following FDA mtg 1Q15 w/ exp completion of filing 3Q15, seeking approval for treatment of rare autoimmune disorder resulting in muscle weakness (LEMS), in OCT12 licensed North American rights from $BMRN (markets drug in Europe), FDA Orphan Drug & Breakthrough Therapy status, Jacobus Pharma developing same drug in a different formulation & provides it free of charge w/ similar regulatory approval filing timeline & first company approved will receive seven-year marketing exclusivity as an Orphan Drug